- Home
- GALT vs SCLXW Comparison
GALT vs SCLXW Comparison
Compare GALT & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | SCLXW |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.3M | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | SCLXW |
|---|---|---|
| Price | $6.25 | $0.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 465.8K | 4.0K |
| Earning Date | 11-14-2025 | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $0.73 | $0.18 |
| 52 Week High | $6.66 | $0.18 |
Technical Indicators
Market Signals| Indicator | GALT | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 41.02 |
| Support Level | $5.10 | $0.17 |
| Resistance Level | $6.32 | $0.21 |
| Average True Range (ATR) | 0.54 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 82.05 | 30.64 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.